National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Front Matter." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
III
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

Committee on Issues and Priorities for New Vaccine Development

SAMUEL L.KATZ (chair),

Department of Pediatrics, Duke University Medical Center

A.JOHN BEALE,

Wellcome Research Laboratories, United Kingdom

MARSHALL H.BECKER,

Department of Health Behavior and Health Education, University of Michigan, Ann Arbor

JAMES CHIN,

Department of Health Services, State of California Health and Welfare Agency, Berkeley

PURNELL W.CHOPPIN,

Howard Hughes Medical Institute, Bethesda, Md.

THEODORE C.EICKHOFF,

Department of Internal Medicine, Presbyterian/St Luke’s Medical Center, Denver

FRANCIS A.ENNIS,

Department of Medicine and Molecular Genetics, University of Massachusetts Medical Center, Worcester

HARVEY V.FINEBERG,

Institute for Health Research, Harvard School of Public Health

MAURICE R.HILLEMAN,

Merck Institute for Therapeutic Research, Merck Sharp & Dohme Research Laboratories

GERALD T.KEUSCH,

Division of Geographic Medicine, Tufts University

RICHARD F.KINGHAM,

Covington and Burling, Washington, D.C.

BERNARD ROIZMAN,

Department of Microbiology and Biophysics, University of Chicago

HENRY R.SHINEFIELD,

Department of Pediatrics, Kaiser Permanente Medical Group, San Francisco

JANE E.SISK,

Office of Technology Assessment, United States Congress

CLADD E.STEVENS,

Laboratory of Epidemiology, The New York Blood Center

LEROY WALTERS,

Kennedy Institute of Ethics, Georgetown University

MILTON C.WEINSTEIN,

Institute for Health Research, Harvard School of Public Health

See Appendix G for further information on committee members.

Institute of Medicine Staff

ROY WIDDUS, Study Director and Director,

Division of International Health

ENRIQUETA C.BOND, Director,

Division of Health Promotion and Disease Prevention

GUTHRIE BIRKHEAD, Consultant

CYNTHIA HOWE, Research Assistant

ELAINE MCGARRAUGH, Staff Associate

EVE K.NICHOLS, Editor

JUDE C.PAYNE, Research Assistant

GAIL E.SPEARS, Administrative Secretary

NORA STEINER, Research Assistant

Page
III
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)